Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could becom...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Akihiro, Matsui, Toshiyuki, Takatsu, Noritaka, Takada, Yasumichi, Kishi, Masahiro, Yano, Yutaka, Beppu, Takahiro, Ono, Yoichiro, Ninomiya, Kazeo, Hirai, Fumihito, Nagahama, Takashi, Hisabe, Takashi, Takaki, Yasuhiro, Yao, Kenshi, Imaeda, Hirotsugu, Andoh, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934595/
https://www.ncbi.nlm.nih.gov/pubmed/29743835
http://dx.doi.org/10.5217/ir.2018.16.2.223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934595/
https://www.ncbi.nlm.nih.gov/pubmed/29743835
http://dx.doi.org/10.5217/ir.2018.16.2.223

Ejemplares similares